Yemen has one of the highest NTD burdens in the Middle East. The Yemen NSCP commenced in December 2010 as a joint initiative between the Ministry of Health (MoH), the World Health Organization (WHO), the World Bank, and Schistosomiasis Control Initiative (SCI). The initiative is a five-year, $28 million, program funded by the World Bank, set to run through 2015. However, World Bank funding is conditional on an independent expert agency providing technical support to the country’s MoH. Therefore, the END Fund support SCI’s efforts to provide technical assistance to the national program, leveraging the World Bank funding.
END Fund Investment
The END Fund has been providing support to the National Schistosomiasis Control Program (NSCP) since 2013. This program targets at-risk children and adults with treatment for schistosomiasis and intestinal worms through multiple mass drug administration (MDA) campaigns. In addition, this investment is contributing to the country’s first efforts to implement a river blindness elimination program.
Program to Date
In 2013, MDA efforts resulted in the treatment of over 9 million individuals including school-age children and adults in 263 endemic districts. In 2014, a review of remapping data showed that although schistosomiasis is still endemic in the country, the distribution is much more restricted and no districts are still classified as high-risk. Intestinal worm infection is also still endemic but most districts are now classified under standard or low risk categories. These results clearly show that ongoing control efforts in Yemen have impacted disease prevalence. The MDA targeted over 4 million individuals for treatment. In addition, plans are underway to pilot a river blindness elimination program.